- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Pooled Analysis Confirms XARELTO® has Similar Efficacy and Reduces the Incidence of Major Bleeding by Nearly Half Compared to Standard of Care in Treatment of DVT and PE
Analysis Published in the Thrombosis Journal
Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.
Late-Stage Prostate Cancer Treatment Strengthens Oncology Pipeline
European Commission Approves VELCADE® As A Frontline Induction Therapy Before Stem Cell Transplantation
Decision could significantly improve transplant outcomes for patients with multiple myeloma
STELARA® Receives CHMP Positive Opinion For Treatment Of Psoriatic Arthritis
STELARA Recommended for Approval in Adult Patients with Active Psoriatic Arthritis
New Data Confirms Circulating Tumor Cells Are Useful Predictors of Progression-free and Overall Survival
First Study to Demonstrate Value of Circulating Tumor Cell Enumeration in Chinese Metastatic Breast Cancer Patients Published in Annals of Oncology
SIMPONI® ARIA™ (golimumab) for infusion Receives FDA Approval for TREATMENT OF MODERATELY TO SEVERELY ACTIVE Rheumatoid arthritis
First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis
New Drug Application Submitted to U.S. FDA for Ibrutinib in the Treatment of Two B-Cell Malignancies
If approved, ibrutinib will address a high unmet need in relapsed/refractory chronic lymphocytic leukemia and relapsed/refractory mantle cell lymphoma